Roula Qaqish

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

Todd T. Brown, Grace A. McComsey, Martin King et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 312 citations

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Jacques Reynes, Roger Trinh, Federico Pulido et al. · AIDS Research and Human Retroviruses · 2012 · 129 citations

Antiretroviral-naive Subjects, Week 96, Human Retrovirus +15

Evaluation of the Factors Influencing Stomach-specific Delivery of Antibacterial Agents for <i>Helicobacter pylori</i> Infection

S. WaqarH. Shah, Roula Qaqish, Vijay R. Patel et al. · Journal of Pharmacy and Pharmacology · 1999 · 97 citations · Full text

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Imam Waked, Gamal Shiha, Roula Qaqish et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 73 citations

Open-label Trial, Hepatology, Hepatitis C +9

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial

Tarik Asselah, Christophe Hézode, Roula Qaqish et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 52 citations

Open-label Trial, Hepatology, Hepatitis C +9